Incurin® Questions and Answers
-
What are the contraindications for Incurin regarding polyuria and polydipsia?
Incurin is indicated for the treatment of incontinence due to urinary sphincter mechanism incompetence (USMI) in ovariohysterectomised bitches.
Urinary incontinence can also be caused by several disorders that do not involve USMI including neurological disorders. It is important to ensure that we are dealing with incontinence due to USMI and not any other disorder prior to starting Incurin treatment.
Polyuria-polydipsia conditions can lead to some owners perceiving ‘incontinence’ because they are seeing the animal having ‘accidents’ in the house because of the production of large volumes of urine, or because their animal is pollakiuric (and so has an increased urge to urinate rather than a loss of voluntary control of urination). Careful clinical history-taking can prove critical in these cases.
Evaluation for the presence of underlying disorders should be of paramount importance in the animal presenting with PUPD and perceived ‘incontinence’. In particular, in the case of PUPD due to diabetes mellitus, failure to diagnose and treat appropriately the PUPD-causing disorder could have severe consequences for the animal e.g. ketoacidosis. Other disorders resulting in PUPD of consideration include renal disease, Cushing’s, UTIs, hypothyroidism. For these, estriol treatment would not be indicated or effective.
-
What is the onset of action for Incurin?
Response to Incurin can be variable and for some dogs full onset of effect can be slower and may only be noted after 4-6 weeks1.
Thus, although dose changes can be made safely prior to this, 4-6 weeks is therefore the minimum trial period recommended to assess initial response to Incurin in dogs slow to show signs of improvement of USMI.
-
How long does Incurin take to leave the system?
From trial work, there was no demonstration of accumulation of estriol over time and therefore once the medication is stopped, the therapeutic effect of Incurin may cease within 24 hours2.
Product images are representations of packaging and may not accurately reflect the current packaging available in the GB marketplace.
Date of preparation: March 2025
Not answered your question?
Email your question and our team will reply within 2 business days.
Contact our Technical Support Team today.
Incurin® contains estriol. POM-V.
Further information is available from the SPC, datasheet or package leaflet.
Advice should be sought from the medicine prescriber.
Prescription decisions are for the person issuing the prescription alone.
Use Medicines Responsibly.
MSD Animal Health UK Limited, Walton Manor, Walton, Milton Keynes, MK7 7AJ, UK
Registered in England & Wales no. 946942
References
1. Chapter VIII PHARMACOKINETICS OF ESTRIOL AND EFFECTS ON URETHRAL CLOSURE AND BLADDER STORAGE FUNCTION IN NEUTERED FEMALE DOGS, PhD thesis for R.F. Nickel, University of Utrecht. Based upon: R.F. Nickel, A.M.T.C. van Wees, W.E. van den Brom, S.J. Dieleman, J. Fink-Gremmels. 1997 The pharmacokinetics and urodynamic effects of orally administered estriol in neutered female dogs.
2. M. Hoeijmakers, B. Janszen , A. Coert, L. Horspool 2003. Pharmacokinetics of oestriol after repeated oral administration to dogs. Research in Veterinary Science. 75 (2003) 55–59